Compare ADMA Biologics Inc (ADMA) vs Roundhill Russell 2000 0DTE Covered Call Strat ETF (RDTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs Roundhill Russell 2000 0DTE Covered Call Strat ETF — how do they compare? ADMA Biologics Inc trades at $9.88 (market cap $2.18B), while Roundhill Russell 2000 0DTE Covered Call Strat ETF trades at $28.93. The key difference: Roundhill Russell 2000 0DTE Covered Call Strat ETF is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | RDTE | |
|---|---|---|
Market Cap | $2.18B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $20.38 | $34.20 |
52-Week Low | $7.60 | $26.40 |
Enterprise Value | $2.25B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.90, down 1.59% today, with strong profitability metrics including 64.71% gross margin and 41.9% ROE. Technical indicators show a bullish trend with support at $9-10, though RSI levels suggest overbought conditions. Recent earnings show mixed results with Q4 2025 beating expectations but Q1 and Q2 2026 missing estimates. The stock faces significant legal headwinds with multiple securities fraud lawsuits filed against the company.
Despite strong fundamentals and bullish analyst consensus (88.9% buy ratings), ADMA faces substantial legal risks from ongoing securities litigation that could impact shareholder value. The company's solid profit margins and growth trajectory provide upside potential, but investors should carefully weigh litigation risks against fundamental strength.
RDTE trades at $28.91, up 1.19% today, but technical indicators signal a bearish trend with moving averages showing significant sell pressure. The stock exhibits a consistent dividend distribution pattern, with multiple payments scheduled through mid-2026. Recent news coverage highlights the ETF's high-yield strategy but raises concerns about structural risks and capital erosion potential.
The outlook remains cautious due to the bearish technical structure and fundamental concerns about the covered-call strategy's sustainability. Investment opportunity exists for income-focused investors attracted to the dividend yield, but risks include capped upside participation and potential NAV deterioration during market rallies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Roundhill Russell 2000 0DTE Covered Call Strat ETF
RDTE is an actively managed ETF that seeks to generate income through a covered call strategy on the Russell 2000 Index. The fund primarily holds a portfolio of short-term U.S. government securities and sells 0-DTE (zero days to expiration) index call options on the Russell 2000. This highly tactical strategy aims to maximize premium capture by exploiting the high time decay of options that are expiring on the same day, which provides enhanced income but also exposes the fund to significant volatility and risks associated with daily options settlement.
Read more on RDTE →
